Martin Ingelsson

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi request reprint Expression of APP pathway mRNAs and proteins in Alzheimer's disease
    Toshifumi Matsui
    Alzheimer Disease Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Brain Res 1161:116-23. 2007
  2. pmc Antibodies against alpha-synuclein reduce oligomerization in living cells
    Thomas Näsström
    Rudbeck Laboratory, Department of Public Health Geriatrics, Uppsala University, Uppsala, Sweden
    PLoS ONE 6:e27230. 2011
  3. pmc Increased mRNA Levels of TCF7L2 and MYC of the Wnt Pathway in Tg-ArcSwe Mice and Alzheimer's Disease Brain
    Elin S Blom
    Section of Molecular Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, 751 85 Uppsala, Sweden
    Int J Alzheimers Dis 2011:936580. 2010
  4. ncbi request reprint No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain
    Martin Ingelsson
    Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
    Acta Neuropathol 112:439-49. 2006
  5. ncbi request reprint Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains
    Martin Ingelsson
    Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
    Acta Neuropathol 114:471-9. 2007
  6. ncbi request reprint [Conformationally altered proteins cause neurodegenerative diseases]
    Martin Ingelsson
    Geriatriska kliniken, AstraZeneca, Uppsala, Sweden
    Lakartidningen 102:3542-3, 3545-6, 3549 passim. 2005
  7. pmc CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid
    Vilmantas Giedraitis
    Uppsala University, Department of Public Health Geriatrics, Rudbeck Laboratory, Uppsala, Sweden
    Neurosci Lett 469:265-7. 2010
  8. doi request reprint No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration
    Lena Skoglund
    Molecular Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, SE 751 85 Uppsala, Sweden
    Dement Geriatr Cogn Disord 28:471-5. 2009
  9. ncbi request reprint Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms
    Jung Lee
    Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
    Exp Neurol 194:91-6. 2005
  10. ncbi request reprint Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels
    Toshifumi Matsui
    Alzheimer Research Unit, Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    J Neuropathol Exp Neurol 65:508-15. 2006

Detail Information

Publications48

  1. ncbi request reprint Expression of APP pathway mRNAs and proteins in Alzheimer's disease
    Toshifumi Matsui
    Alzheimer Disease Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Brain Res 1161:116-23. 2007
    ..These results suggest that altered transcription of APP in AD is proportionately associated with Abeta peptide, may occur in the context of gliosis, and may contribute to Abeta deposition in sporadic AD...
  2. pmc Antibodies against alpha-synuclein reduce oligomerization in living cells
    Thomas Näsström
    Rudbeck Laboratory, Department of Public Health Geriatrics, Uppsala University, Uppsala, Sweden
    PLoS ONE 6:e27230. 2011
    ....
  3. pmc Increased mRNA Levels of TCF7L2 and MYC of the Wnt Pathway in Tg-ArcSwe Mice and Alzheimer's Disease Brain
    Elin S Blom
    Section of Molecular Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, 751 85 Uppsala, Sweden
    Int J Alzheimers Dis 2011:936580. 2010
    ..Increased mRNA levels of dihydropyrimidinase-like 3 were observed in AD brain, suggesting that altered Wnt pathway regulation may signify synaptic rearrangement or neurogenesis...
  4. ncbi request reprint No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain
    Martin Ingelsson
    Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
    Acta Neuropathol 112:439-49. 2006
    ..In conclusion, this study indicated region-specific and possibly cell-type-specific tau splicing but did not lend any support to overt changes in alternative splicing of tau exon 10 being an underlying factor in AD pathogenesis...
  5. ncbi request reprint Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains
    Martin Ingelsson
    Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
    Acta Neuropathol 114:471-9. 2007
    ..In conclusion, we demonstrated increased but largely variable 4R tau/3R tau mRNA ratios in FTLD and PSP cases, suggesting heterogeneous pathophysiological processes within these disorders...
  6. ncbi request reprint [Conformationally altered proteins cause neurodegenerative diseases]
    Martin Ingelsson
    Geriatriska kliniken, AstraZeneca, Uppsala, Sweden
    Lakartidningen 102:3542-3, 3545-6, 3549 passim. 2005
    ..As of today, only symptomatic pharmacotherapies are available, but new insights into the underlying molecular mechanisms are providing strategies to prevent or even cure these devastating disorders...
  7. pmc CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid
    Vilmantas Giedraitis
    Uppsala University, Department of Public Health Geriatrics, Rudbeck Laboratory, Uppsala, Sweden
    Neurosci Lett 469:265-7. 2010
    ..In conclusion, we found no evidence that CALHM1 P86L is associated with altered CSF levels of the investigated AD biomarkers...
  8. doi request reprint No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration
    Lena Skoglund
    Molecular Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, SE 751 85 Uppsala, Sweden
    Dement Geriatr Cogn Disord 28:471-5. 2009
    ..In this study, we investigated 39 patients with FTLD, previously found negative for mutations in PGRN and MAPT, for copy number alterations of these 2 genes...
  9. ncbi request reprint Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms
    Jung Lee
    Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
    Exp Neurol 194:91-6. 2005
    ..The results suggest that the investigated BDNF polymorphisms are neither robust genetic risk factors nor determinants of BDNF protein levels in AD...
  10. ncbi request reprint Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels
    Toshifumi Matsui
    Alzheimer Research Unit, Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    J Neuropathol Exp Neurol 65:508-15. 2006
    ..Thus, a principal caspase pathway from caspase-8 to caspase-3 and/or 7 may contribute to neuron loss in AD brain...
  11. doi request reprint Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls
    Johan Sundelöf
    Uppsala University, Department of Public Health Geriatrics, Uppsala, Sweden
    J Alzheimers Dis 22:1223-30. 2010
    ..Further investigation of cathepsin B as a predictor of AD is warranted...
  12. doi request reprint Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype
    Elin S Blom
    Section of Molecular Geriatrics, Department of Public Health, Uppsala University, Uppsala, Sweden
    Dement Geriatr Cogn Disord 27:458-64. 2009
    ..Here, we investigated these markers to assess their predictive value and influence on the rate of disease progression...
  13. doi request reprint Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation
    Lena Skoglund
    Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
    Neurogenetics 10:27-34. 2009
    ..In conclusion, the PGRN Gly35fs mutation causes frontotemporal dementia with variable clinical presentation in a large Swedish family, most likely through nonsense-mediated decay of mutant PGRN mRNA and resulting haploinsufficiency...
  14. doi request reprint Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls
    Johan Sundelöf
    Uppsala University, Department of Public Health Geriatrics, Uppsala, Sweden
    J Alzheimers Dis 21:471-8. 2010
    ..Interestingly, cystatin C levels were positively correlated with both tau and Abeta42 levels in CSF independent of age, gender, and APOE genotype...
  15. pmc Novel progranulin mutation detected in 2 patients with FTLD
    Lena Skoglund
    Molecular Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
    Alzheimer Dis Assoc Disord 25:173-8. 2011
    ..From the screening of these 51 FTLD patients, we could also identify the earlier reported mutation Gln130fs, and several coding sequence variants that are most likely nonpathogenic...
  16. ncbi request reprint Single molecule profiling of tau gene expression in Alzheimer's disease
    Chris Conrad
    Department of Neurology, MassGeneral Institute for Neurodegenerative Disease MIND, Charlestown, Massachusetts, USA
    J Neurochem 103:1228-36. 2007
    ..Furthermore, splicing-based therapeutics is an emerging area of drug development, and a well-defined and quantitative assay for monitoring single-gene transcriptome will be relevant for such development...
  17. pmc Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells
    Paul O'Callaghan
    Department of Public Health and Caring Sciences, Division of Molecular Geriatrics, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Brain Pathol 18:548-61. 2008
    ..In mouse primary glial cultures, we observed increased levels of GPC1 and SDC3 following Abeta stimulation. These results suggest that HS codeposits with Abeta40 in neuritic plaques and is mainly derived from glial cells...
  18. doi request reprint A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice
    Ola Philipson
    Department of Public Health and Caring Science, Uppsala University, Sweden
    Neurobiol Aging 30:1393-405. 2009
    ..TgAPP-ArcSwe, with its insoluble state of deposited Abeta, could serve as a complementary model to better predict the outcome of clinical trials...
  19. ncbi request reprint The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease
    Vilmantas Giedraitis
    Department of Public Health Geriatrics, Uppsala University, Uppsala, Sweden
    Neurosci Lett 427:127-31. 2007
    ..Our findings suggest that the normal equilibrium between CSF and plasma Abeta may be disrupted with the initiation of amyloid deposition in the brain...
  20. doi request reprint Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study
    Johan Sundelöf
    Uppsala University, Department of Public Health and Geriatrics, Uppsala Science Park, Dag Hammarskölds väg 14B, Uppsala, Sweden
    Arch Neurol 65:256-63. 2008
    ..Beta amyloid (Abeta) protein accumulates in the brains of individuals with Alzheimer disease (AD) and is detectable in cerebrospinal fluid and plasma...
  21. ncbi request reprint Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease
    Martin Ingelsson
    Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
    Neurosci Lett 367:228-31. 2004
    ..Despite growing evidence implicating cholesterol metabolism in AD risk and Abeta generation, our data does not support a robust genetic relationship between the CYP46 intron 2 polymorphism and AD risk or neuropathology...
  22. pmc Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation
    Dag Sehlin
    Molecular Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
    PLoS ONE 7:e32014. 2012
    ....
  23. ncbi request reprint Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease
    Elin S Blom
    Section of Molecular Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
    Eur J Hum Genet 16:171-5. 2008
    ..No duplications of APP were identified, whereby we conclude that this is not a common cause of EOAD in the Swedish and Finnish populations, at least not in our collection of families and cases...
  24. doi request reprint Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro
    Hedvig Welander
    Department of Public Health Molecular Geriatrics, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Biochem Biophys Res Commun 412:32-8. 2011
    ..Further studies on gelsolin and other Lewy body associated proteins are warranted to learn more about their potential role in the α-synuclein aggregation process...
  25. doi request reprint The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties
    Thomas Näsström
    Department of Public Health and Caring Sciences, Uppsala University, Rudbeck Laboratory, 751 85 Uppsala, Sweden
    Free Radic Biol Med 50:428-37. 2011
    ..Despite nearly identical chemical structures, ONE and HNE induce the formation of off-pathway α-synuclein oligomers with distinct biochemical, morphological, and functional properties...
  26. ncbi request reprint Alpha-synuclein and chaperones in dementia with Lewy bodies
    Ippolita Cantuti-Castelvetri
    Massachusetts General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    J Neuropathol Exp Neurol 64:1058-66. 2005
    ..However, this reduced clearance cannot be attributed to a failure of chaperone expression, because their mRNA is unchanged or increased in the DLB brain...
  27. doi request reprint Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation
    Therese Fagerqvist
    Department of Public Health and Caring Sciences, Molecular Geriatrics, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Neurochem 126:131-44. 2013
    ..Moreover, they could be potential candidates both for immunotherapy and as reagents in an assay to assess a potential disease biomarker...
  28. doi request reprint The Arctic amyloid-β precursor protein (AβPP) mutation results in distinct plaques and accumulation of N- and C-truncated Aβ
    Ola Philipson
    Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
    Neurobiol Aging 33:1010.e1-13. 2012
    ..Our findings are discussed in relation to mechanisms and relevance of amyloid formation and to the clinical features of AD...
  29. doi request reprint Genotyping of apolipoprotein E: comparative evaluation of different protocols
    Martin Ingelsson
    Harvard Medical School Massachusetts General Hospital, Charlestown, Massachusetts, USA
    Curr Protoc Hum Genet . 2003
    ..The latter approaches also provide the flexibility to investigate other polymorphic disease markers...
  30. ncbi request reprint Family-based association between Alzheimer's disease and variants in UBQLN1
    Lars Bertram
    Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown 02129, USA
    N Engl J Med 352:884-94. 2005
    ..The gene encoding ubiquilin 1 (UBQLN1) is one of several candidate genes for Alzheimer's disease located near a well-established linkage peak on chromosome 9q22...
  31. pmc Increased inflammatory response in cytomegalovirus seropositive patients with Alzheimer's disease
    Gabriel Westman
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    PLoS ONE 9:e96779. 2014
    ..Further studies of AD patients at earlier stages of disease, could provide better insight into the pathophysiology. ..
  32. ncbi request reprint Disordered proteins in dementia
    Martin Ingelsson
    Harvard Medical School, Massachusetts General Hospital, Charlestown 02129, USA
    Ann Med 34:259-71. 2002
    ..As of today, no efficient pharmacotherapies are available, but new insights into the underlying molecular mechanisms are providing strategies to prevent or even cure these devastating disorders...
  33. doi request reprint Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders
    Veronica Lindström
    Department of Public Health Geriatrics, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden
    Immunotherapy 6:141-53. 2014
    ..Thus, immunotherapy targeting α-synuclein holds promise, but needs to be further developed as a future disease-modifying treatment in Parkinson's disease and other α-synucleinopathies. ..
  34. ncbi request reprint Transcriptional and conformational changes of the tau molecule in Alzheimer's disease
    Bradley T Hyman
    Department of Neurology, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
    Biochim Biophys Acta 1739:150-7. 2005
    ....
  35. doi request reprint Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo
    Therese Fagerqvist
    Department of Public Health Geriatrics, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Amyloid 20:233-44. 2013
    ..Taken together, we could observe a seeding effect of the ONE-induced α-synuclein oligomers in a fibrillization assay, but neither in a cell nor in a mouse model...
  36. ncbi request reprint Interference from heterophilic antibodies in amyloid-β oligomer ELISAs
    Dag Sehlin
    Department of Public Health and Caring Sciences Molecular Geriatrics, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Alzheimers Dis 21:1295-301. 2010
    ..Taken together, HA interference is a problem that needs to be addressed when measuring low levels of an antigen in human plasma and CSF samples...
  37. ncbi request reprint Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families
    Minji Kim
    Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts 02129, and Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington 40536, USA
    J Biol Chem 282:7825-32. 2007
    ....
  38. pmc Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease
    Hans Basun
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
    Arch Neurol 65:499-505. 2008
    ..Most of these mutations may also cause cognitive impairment, but the Arctic APP mutation is the only known intra-beta-amyloid mutation to date causing the more typical clinical picture of Alzheimer disease...
  39. pmc Decreased proportion of cytomegalovirus specific CD8 T-cells but no signs of general immunosenescence in Alzheimer's disease
    Gabriel Westman
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    PLoS ONE 8:e77921. 2013
    ..Interestingly, patients with AD showed a decreased proportion of CMV-specific CD8 cells but no difference in general CD8 differentiation. ..
  40. doi request reprint The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers
    Tomas Näsström
    Department of Public Health and Caring Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Biochem Biophys Res Commun 378:872-6. 2009
    ..Despite prolonged incubation the oligomers did not continue to aggregate into a fibrillar state, thus suggesting that these alpha-synuclein species were not on a fibrillogenic pathway...
  41. pmc Transcriptional up-regulation and activation of initiating caspases in experimental glaucoma
    Wei Huang
    Howe Laboratory of Opthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA
    Am J Pathol 167:673-81. 2005
    ..These data suggest that elevated IOP activates a transcriptional up-regulation and activation of initiating caspases in RGCs and triggers apoptosis through both extrinsic and intrinsic caspase cascades...
  42. pmc The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide
    Stephanie J Soscia
    Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease and Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America
    PLoS ONE 5:e9505. 2010
    ....
  43. ncbi request reprint APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis
    Hiroaki Fukumoto
    Alzheimer Disease Research Unit, Massachusetts General Hospital East, B114 2010, 114 16th St, Charlestown, MA 02129, USA
    Exp Neurol 183:249-53. 2003
    ..However, the greater proportion of apoE4 in the cerebrospinal fluid suggests differential production or metabolism of the protein in the central nervous system (CNS), with the apoE4 isoform dominating...
  44. pmc Age-related somatic structural changes in the nuclear genome of human blood cells
    Lars A Forsberg
    Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Sweden
    Am J Hum Genet 90:217-28. 2012
    ..Our work might also help to explain the cause of an age-related reduction in the number of cell clones in the blood; such a reduction is one of the hallmarks of immunosenescence...
  45. ncbi request reprint Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry
    Sravani Musunuri
    Analytical Chemistry, Department of Chemistry BMC and Department Public Health Geriatrics, Uppsala University, Uppsala, Sweden
    J Proteome Res 13:2056-68. 2014
    ..Apart from leading to new insights into the molecular mechanisms in AD, the findings provide us with possible novel candidates for future diagnostic and prognostic disease markers. ..
  46. pmc Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy
    Daniel A Dombeck
    School of Applied and Engineering Physics, Cornell University, Ithaca, NY 14853, USA
    Proc Natl Acad Sci U S A 100:7081-6. 2003
    ..SHG imaging provides a tool to investigate the kinetics and function of MT ensemble polarity in dynamic native brain tissue structures and other subcellular motility structures based on polarized MTs...
  47. ncbi request reprint Association study of cholesterol-related genes in Alzheimer's disease
    M Axel Wollmer
    Division of Psychiatry Research, University of Zurich, August Forel Str 1, 8008 Zurich, Switzerland
    Neurogenetics 8:179-88. 2007
    ..004). We conclude that genetic variants investigated in this study may be associated with a moderate modification of the risk for AD in some samples...